NO20091045L - 3-Pyridinkarboksamid- og 2-pyrazinkarboksamid-derivatives som HDL.kolesterol-okende midler - Google Patents

3-Pyridinkarboksamid- og 2-pyrazinkarboksamid-derivatives som HDL.kolesterol-okende midler

Info

Publication number: NO20091045L
Authority: NO; Norway
Prior art keywords: hdl cholesterol; angioplasty; pyridinecarboxamide; increasing agents; pyrazinecarboxamide derivatives
Prior art date: 2006-10-04

Application number

NO20091045A

Other languages

English (en)

Norwegian (no)

Inventor

Paul Hebeisen

Stephan Roever

Matthias Heinrich Nettekoven

Ulrike Obst Sander

Mirjana Andjelkovic

Agnes Benardeau

Evelyne Chaput

Constantinos G Panousis

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-04

Filing date

2009-03-10

Publication date

2009-03-31

2009-03-10 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2009-03-31 Publication of NO20091045L publication Critical patent/NO20091045L/no

Links

DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title 2
239000003795 chemical substances by application Substances 0.000 title 1
229960003966 nicotinamide Drugs 0.000 title 1
235000005152 nicotinamide Nutrition 0.000 title 1
239000011570 nicotinamide Substances 0.000 title 1
IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical class NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 title 1
238000002399 angioplasty Methods 0.000 abstract 3
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
206010002383 Angina Pectoris Diseases 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
208000032928 Dyslipidaemia Diseases 0.000 abstract 1
239000004131 EU approved raising agent Substances 0.000 abstract 1
208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
208000000563 Hyperlipoproteinemia Type II Diseases 0.000 abstract 1
208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
206010063837 Reperfusion injury Diseases 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
206010045261 Type IIa hyperlipidaemia Diseases 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000006806 disease prevention Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
201000001386 familial hypercholesterolemia Diseases 0.000 abstract 1
235000010855 food raising agent Nutrition 0.000 abstract 1
208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
208000028867 ischemia Diseases 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
208000031225 myocardial ischemia Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20091045A 2006-10-04 2009-03-10 3-Pyridinkarboksamid- og 2-pyrazinkarboksamid-derivatives som HDL.kolesterol-okende midler NO20091045L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06121755		2006-10-04
PCT/EP2007/060094 WO2008040651A1 (en)	2006-10-04	2007-09-24	3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents

Publications (1)

Publication Number	Publication Date
NO20091045L true NO20091045L (no)	2009-03-31

Family

ID=38740266

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20091045A NO20091045L (no)	2006-10-04	2009-03-10	3-Pyridinkarboksamid- og 2-pyrazinkarboksamid-derivatives som HDL.kolesterol-okende midler

Country Status (14)

Country	Link
US (3)	US20080085906A1 (pt)
EP (2)	EP2074096B1 (pt)
JP (1)	JP2010505789A (pt)
KR (1)	KR101107896B1 (pt)
CN (1)	CN101522626A (pt)
AU (1)	AU2007304365A1 (pt)
BR (1)	BRPI0717845A2 (pt)
CA (1)	CA2664119A1 (pt)
IL (1)	IL197577A0 (pt)
MX (1)	MX2009003222A (pt)
NO (1)	NO20091045L (pt)
RU (1)	RU2454405C2 (pt)
WO (1)	WO2008040651A1 (pt)
ZA (1)	ZA200902353B (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2007007101A (es)	2004-12-14	2007-08-21	Astrazeneca Ab	Derivados de oxadiazol como inhibidores de acil coa:diacilglicerol aciltransferasa.
AR058562A1 (es)	2005-12-22	2008-02-13	Astrazeneca Ab	Derivados de pirimido [4,5 b] (1,4) oxazinas , procedimientos de obtencion y su uso como inhibidores de acetil coa y dgat 1
BRPI0712802A2 (pt)	2006-05-30	2012-10-23	Astrazeneca Ab	composto, métodos para produzir uma inibição da atividade de dgat1, e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para preparar um composto
CA2651663A1 (en)	2006-05-30	2007-12-06	Astrazeneca Ab	Chemical compounds
US7781593B2 (en) *	2006-09-14	2010-08-24	Hoffmann-La Roche Inc.	5-phenyl-nicotinamide derivatives
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101932562B (zh)	2007-12-20	2013-06-12	阿斯利康(瑞典)有限公司	作为dgat1抑制剂190的氨基甲酰基化合物
US7897621B2 (en) *	2008-03-31	2011-03-01	Hoffmann-La Roche Inc.	2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents
US8088920B2 (en) *	2008-03-31	2012-01-03	Hoffmann-La Roche Inc.	3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents
MX2011004953A (es)	2008-11-10	2011-12-14	Vertex Pharma	Compuestos utiles como inhibidores de cinasa atr.
ES2921576T3 (es)	2008-12-19	2022-08-29	Vertex Pharma	Compuestos útiles como inhibidores de la quinasa ATR
US8338441B2 (en) *	2009-05-15	2012-12-25	Gilead Sciences, Inc.	Inhibitors of human immunodeficiency virus replication
WO2010146395A1 (en)	2009-06-19	2010-12-23	Astrazeneca Ab	Pyrazine carboxamides as inhibitors of dgat1
UA107088C2 (xx) *	2009-09-11	2014-11-25		5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину
US8969356B2 (en)	2010-05-12	2015-03-03	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
EP2569286B1 (en)	2010-05-12	2014-08-20	Vertex Pharmaceuticals Inc.	Compounds useful as inhibitors of atr kinase
EP2569313A1 (en)	2010-05-12	2013-03-20	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
WO2011143419A1 (en) *	2010-05-12	2011-11-17	Vertex Pharmaceuticals Incorporated	Pyrazines useful as inhibitors of atr kinase
NZ603478A (en)	2010-05-12	2014-09-26	Vertex Pharma	2 -aminopyridine derivatives useful as inhibitors of atr kinase
US9334244B2 (en)	2010-05-12	2016-05-10	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2585468A1 (en)	2010-06-23	2013-05-01	Vertex Pharmaceuticals Incorporated	Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
WO2012031817A1 (en) *	2010-09-09	2012-03-15	F. Hoffmann-La Roche Ag	Determination of abca1 protein levels in cells
US8410107B2 (en)	2010-10-15	2013-04-02	Hoffmann-La Roche Inc.	N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US20120101282A1 (en) *	2010-10-22	2012-04-26	Pascal Dott	Process for the preparation of nicotinamide derivatives
US8669254B2 (en) *	2010-12-15	2014-03-11	Hoffman-La Roche Inc.	Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
AU2012240030A1 (en)	2011-04-05	2013-10-24	Vertex Pharmaceuticals Incorporated	Aminopyrazine compounds useful as inhibitors of TRA kinase
US9309250B2 (en)	2011-06-22	2016-04-12	Vertex Pharmaceuticals Incorporated	Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
WO2012178123A1 (en)	2011-06-22	2012-12-27	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
EP2723747A1 (en)	2011-06-22	2014-04-30	Vertex Pharmaceuticals Inc.	Compounds useful as inhibitors of atr kinase
CA2844835A1 (en)	2011-09-12	2013-03-21	Uwe Grether	N-(5-cycloalkyl- or 5-heterocyclyl-)-pyridin-3-yl carboxamides
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
BR112014005637A2 (pt) *	2011-09-12	2017-03-28	Hoffmann La Roche	5-cicloalquila- ou 5-heterociclila-nicotinamidas
WO2013037703A1 (en) *	2011-09-12	2013-03-21	F. Hoffmann-La Roche Ag	3 -pyridine carboxylic acid hydrazides as hdl-cholesterol raising agents
CA2850564A1 (en)	2011-09-30	2013-04-04	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
US8765751B2 (en)	2011-09-30	2014-07-01	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
WO2013049720A1 (en)	2011-09-30	2013-04-04	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
RU2018108589A (ru)	2011-09-30	2019-02-25	Вертекс Фармасьютикалз Инкорпорейтед	Лечение рака поджелудочной железы и немелкоклеточного рака легкого ингибиторами atr
EP3878851A1 (en)	2011-09-30	2021-09-15	Vertex Pharmaceuticals Incorporated	Process for making compounds useful as inhibitors of atr kinase
US9403808B2 (en) *	2011-10-28	2016-08-02	Hoffmann-La Roche Inc.	Pyrazine derivatives
WO2013071090A1 (en)	2011-11-09	2013-05-16	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
JP2015502925A (ja)	2011-11-09	2015-01-29	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ａｔｒキナーゼの阻害剤として有用なピラジン化合物
EP2776420A1 (en)	2011-11-09	2014-09-17	Vertex Pharmaceuticals Incorporated	Pyrazine compounds useful as inhibitors of atr kinase
EP2776429A1 (en)	2011-11-09	2014-09-17	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
US8846917B2 (en)	2011-11-09	2014-09-30	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
PT2833973T (pt)	2012-04-05	2017-12-21	Vertex Pharma	Compostos úteis como inibidores da cinase atr e terapias de combinação dos mesmos
CA2880477A1 (en) *	2012-08-23	2014-02-27	F. Hoffmann-La Roche Ag	Novel phenyl-pyridine/pyrazine amides for the treatment of cancer
WO2014055756A1 (en)	2012-10-04	2014-04-10	Vertex Pharmaceuticals Incorporated	Method for measuring atr inhibition mediated increases in dna damage
EP2909202A1 (en)	2012-10-16	2015-08-26	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
WO2014089379A1 (en)	2012-12-07	2014-06-12	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
CN108299400B (zh)	2013-03-14	2021-02-19	达特神经科学(开曼)有限公司	作为pde4抑制剂的取代的吡啶和取代的吡嗪化合物
US9663519B2 (en)	2013-03-15	2017-05-30	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
WO2015085132A1 (en)	2013-12-06	2015-06-11	Vertex Pharmaceuticals Incorporated	2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
HRP20200186T1 (hr)	2014-06-05	2020-05-29	Vertex Pharmaceuticals Inc.	Radioaktivno obilježeni derivati 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-karboksamid spojeva koji se koriste kao inhibitori atr kinaze, priprava navedenih spojeva i njihovi različiti čvrsti oblici
JP6936007B2 (ja)	2014-06-17	2021-09-15	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ｃｈｋ１阻害剤とａｔｒ阻害剤との組み合わせを使用してがんを処置する方法
CA2970011C (en) *	2014-12-24	2021-08-03	Lg Chem, Ltd.	Biaryl derivative as gpr120 agonist
TWI730002B (zh)	2015-09-18	2021-06-11	日商科研製藥股份有限公司	聯芳系化合物及含有此化合物之醫藥
EP3355926B1 (en)	2015-09-30	2025-12-24	Vertex Pharmaceuticals Inc.	Combination of dna damaging agents and atr inhibitors for use in a method for treating cancer using
WO2019084681A1 (en)	2017-10-30	2019-05-09	Montreal Heart Institute	Methods of treating elevated plasma cholesterol
PL237374B1 (pl) *	2017-11-10	2021-04-06	Lambdafin Spolka Z Ograniczona Odpowiedzialnoscia	Kompozycja farmaceutyczna zawierająca mieszaninę estru etylowego kwasu eikozapentaenowego i estru etylowego kwasu dokozaheksaenowego oraz jej zastosowanie
WO2024003259A1 (en) *	2022-06-30	2024-01-04	Bayer Aktiengesellschaft	Tead inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0104332D0 (sv) *	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
SE0104330D0 (sv) *	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
AU2004247615B2 (en) *	2003-06-18	2008-02-21	Astrazeneca Ab	2-substituted 5,6-diaryl-pyrazine derivatives as CB1 modulators
DK1868999T3 (da)	2005-04-06	2009-08-17	Hoffmann La Roche	Pyridin-3-carboxamidderivater som omvendte CB1-agonister
WO2007011760A2 (en) *	2005-07-15	2007-01-25	Kalypsys, Inc.	Inhibitors of mitotic kinesin
US7629346B2 (en)	2006-06-19	2009-12-08	Hoffmann-La Roche Inc.	Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en) *	2006-09-14	2010-08-24	Hoffmann-La Roche Inc.	5-phenyl-nicotinamide derivatives
WO2008040649A2 (en) *	2006-10-04	2008-04-10	F. Hoffmann-La Roche Ag	Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
US8088920B2 (en)	2008-03-31	2012-01-03	Hoffmann-La Roche Inc.	3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents

2007
- 2007-09-24 BR BRPI0717845-0A patent/BRPI0717845A2/pt not_active IP Right Cessation
- 2007-09-24 WO PCT/EP2007/060094 patent/WO2008040651A1/en not_active Ceased
- 2007-09-24 CN CNA2007800369086A patent/CN101522626A/zh active Pending
- 2007-09-24 AU AU2007304365A patent/AU2007304365A1/en not_active Abandoned
- 2007-09-24 EP EP07820501A patent/EP2074096B1/en not_active Not-in-force
- 2007-09-24 RU RU2009116670/04A patent/RU2454405C2/ru not_active IP Right Cessation
- 2007-09-24 JP JP2009530843A patent/JP2010505789A/ja active Pending
- 2007-09-24 KR KR1020097009023A patent/KR101107896B1/ko not_active Expired - Fee Related
- 2007-09-24 MX MX2009003222A patent/MX2009003222A/es active IP Right Grant
- 2007-09-24 EP EP12153000A patent/EP2450350A1/en not_active Withdrawn
- 2007-09-24 CA CA002664119A patent/CA2664119A1/en not_active Abandoned
- 2007-09-27 US US11/904,425 patent/US20080085906A1/en not_active Abandoned
2009
- 2009-02-06 US US12/366,692 patent/US7812028B2/en not_active Expired - Fee Related
- 2009-03-10 NO NO20091045A patent/NO20091045L/no not_active Application Discontinuation
- 2009-03-12 IL IL197577A patent/IL197577A0/en unknown
- 2009-04-03 ZA ZA200902353A patent/ZA200902353B/xx unknown
2010
- 2010-06-29 US US12/825,374 patent/US8188093B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7812028B2 (en)	2010-10-12
ZA200902353B (en)	2010-04-28
US8188093B2 (en)	2012-05-29
CA2664119A1 (en)	2008-04-10
JP2010505789A (ja)	2010-02-25
KR20090075852A (ko)	2009-07-09
US20100267745A1 (en)	2010-10-21
MX2009003222A (es)	2009-04-06
AU2007304365A1 (en)	2008-04-10
RU2009116670A (ru)	2010-11-10
EP2074096B1 (en)	2012-06-27
RU2454405C2 (ru)	2012-06-27
BRPI0717845A2 (pt)	2015-06-16
US20090143409A1 (en)	2009-06-04
WO2008040651A1 (en)	2008-04-10
US20080085906A1 (en)	2008-04-10
IL197577A0 (en)	2009-12-24
KR101107896B1 (ko)	2012-01-25
CN101522626A (zh)	2009-09-02
EP2074096A1 (en)	2009-07-01
EP2450350A1 (en)	2012-05-09

Legal Events

Date	Code	Title	Description
2014-04-28	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20091045L (no)	2009-03-31	3-Pyridinkarboksamid- og 2-pyrazinkarboksamid-derivatives som HDL.kolesterol-okende midler
PH12013502156A1 (en)	2014-01-06	1,3-oxazines as bace1 and/or bace2 inhibitors
IN2012DN00766A (pt)	2015-06-26
MX2013014007A (es)	2014-03-12	[1,3] oxazinas.
EA201391786A1 (ru)	2014-04-30	Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
WO2012104263A3 (en)	2012-09-27	1,4 oxazines as bace1 and/or bace2 inhibitors
MX2013007558A (es)	2013-08-21	1,4-oxazinas como inhibidores de los genes enzima de segmentacion de la proteina precursora del sitio 1 y/o 2 (bace1 y/o bace2).
IN2012DN03043A (pt)	2015-07-31
PH12013502090A1 (en)	2018-03-21	1,3 oxazines as bace1 and/or bace2 inhibitors
MX2013008213A (es)	2013-08-09	N-[3-(5-amino-3,3a,7,7a-tetrahidro-1h-2,4-dioxa-6-aza-inden-7-il) -fenil]-amidas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
PH12013502262A1 (en)	2016-01-22	Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors
WO2010057101A3 (en)	2010-07-15	Compounds useful as hiv blockers
MX2013014194A (es)	2014-03-21	1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2).
EP2571876A4 (en)	2013-12-25	SUBSTITUTED SEVEN-HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES
EA201000365A1 (ru)	2010-10-29	Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза
WO2009111700A3 (en)	2010-03-04	Oxadiazoanthracene compounds for the treatment of diabetes
NO20081729L (no)	2008-05-16	Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
WO2007097931A3 (en)	2007-11-22	Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007136603A3 (en)	2008-01-17	Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EA201270215A1 (ru)	2012-11-30	Apaf-1 ингибиторные соединения
WO2008127682A3 (en)	2009-05-07	Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
PH12014501334A1 (en)	2014-09-15	Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines
PH12015500471A1 (en)	2015-04-20	Therapeutic agent for dyslipidemia
MX2014003408A (es)	2014-04-10	N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1).
ATE432260T1 (de)	2009-06-15	Pyridinderivate als pkc-theta-hemmer